Tisch MS Research Center of New York

Medical Research Servicestischms.org

Tisch MS Research Center of New York is an independent 501(c)(3) nonprofit research institute dedicated to finding the cause and cure of multiple sclerosis, operating an integrated bench-to-bedside model with the affiliated IMSMP clinical practice serving 4,500+ MS patients from 31 countries.

Company typePrivate
Founded2006
HeadquartersNew York, United States
Headcount101–250
GTM typeB2B and B2C
OfferingServices

What Tisch MS Research Center of New York does

Tisch MS Research Center of New York (Tisch MSRCNY) is an independent 501(c)(3) nonprofit research institute founded in 2006 by Dr. Saud Sadiq and co-located with the International Multiple Sclerosis Management Practice (IMSMP). The organization operates from an 80,000-square-foot facility at 521 West 57th Street in New York, combining a clinical practice that serves over 4,500 MS patients from 31 countries with a research operation employing 23 full-time researchers and supporting a research assistant program that has trained over 140 early-career scientists. Its core research spans five tracks: mesenchymal stem cell-derived neural progenitor (MSC-NP) therapy with the first-ever FDA-approved Phase II trial for progressive MS; patient-specific cerebral and spinal cord organoids; the world's first PPMS-specific animal model; CSF-based biomarker and B-cell antibody research; and EBV-pathogenesis investigations.

The underlying technology platform combines wet-lab regenerative medicine with patient-derived disease modeling: autologous MSC-NPs manufactured in a clinical-grade regenerative medicine laboratory, 3D cerebral and spinal cord organoids grown from patient pluripotent stem cells, a first-of-its-kind PPMS mouse model, and an integrated CSF bank and B-cell library. Notable technical milestones include the first FDA-approved Phase I (2014) and Phase II (initiated 2018, results published 2024) MSC-NP clinical trials for progressive MS, the March 2026 publication identifying p21 protein dysregulation as a myelin repair failure mechanism in PPMS, and ongoing work in CSF filtration/pheresis as a therapeutic strategy through the Neurapheresis Research Consortium.

Tisch MSRCNY's business model is a hybrid nonprofit funding stack: private philanthropy and donations (including the Tisch family's naming support in 2013), foundation and government grants secured principally through Dr. Sadiq's network, and clinical care revenue from the affiliated IMSMP practice. Specific revenue figures are not publicly disclosed, though audited financials are available on the website. The center does not sell commercial products; treatment is provided at no cost to clinical trial participants. Customer segments are MS patients (across all subtypes) seeking specialized care and trial access, and research/academic institutions (Wistar Institute, McGill University) engaging in collaborative translational research.

Tisch MS Research Center of New York firmographics

Firmographics

Name: Tisch MS Research Center of New York
Legal name: Tisch Multiple Sclerosis Research Center of New York
Website: https://tischms.org
Company type: Private
Founded year: 2006
Operating status: Operating
Headcount range: 101–250 employees
Short description: Tisch MS Research Center of New York is an independent 501(c)(3) nonprofit research institute dedicated to finding the cause and cure of multiple sclerosis, operating an integrated bench-to-bedside model with the affiliated IMSMP clinical practice serving 4,500+ MS patients from 31 countries.
Ownership category
akta.pro rank

Tisch MS Research Center of New York industry classification

Industry

Product category: Medical Research Services
NAICS: Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC: Services-Health Services (8000)
akta.pro primary industry: Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

Keywords

Multiple sclerosis research
Stem cell clinical trials
Neuroscience research
Regenerative medicine
Progressive MS treatment

Where Tisch MS Research Center of New York is headquartered

Location

Headquarters

HQ city: New York
HQ country: United States
HQ region: North America

Offices1 record

Markets served

Tisch MS Research Center of New York business model

Business model

GTM type: B2B and B2C
Offering type: Services
Cost components: Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

Private Philanthropy and Donations: Tax-deductible donations from individuals, corporate matching gift programs, and planned giving through wills and estate plans support the nonprofit research center.
Foundation and Government Grants: Research programs supported by foundation grants and philanthropic foundation funding. Dr. Sadiq has secured extensive foundation and philanthropic support.
Clinical Care Revenue: Revenue from the affiliated International Multiple Sclerosis Management Practice (IMSMP) provides clinical care to over 4,500 patients from 31 countries, supporting the integrated research model.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Tisch MS Research Center of New York product offering

Product offering

Core offering

Tisch MS Research Center of New York is an independent 501(c)(3) nonprofit research institute dedicated to finding the cause of and cure for multiple sclerosis. It conducts industry-leading medical research across five tracks (Stem Cells, Animal Modeling, Progression, Root Cause, EBV, Organoids) and translates findings from lab bench to bedside through its affiliated clinical practice, IMSMP, which provides specialized MS care to over 4,500 patients from 31 countries.

Product overview

Tisch MSRCNY is an independent 501(c)(3) nonprofit research institute dedicated to finding the cause of and cure for multiple sclerosis. The organization operates a bench-to-bedside model through its affiliated clinical practice, IMSMP. The core research portfolio centers on five key areas: Stem Cell Clinical Trials (using MSC-NP therapy for progressive MS), Organoid Modeling (patient-specific 3D brain/spinal cord models), PPMS Animal Modeling (world's first PPMS-specific animal model), B-cell/Antibody Research (characterizing immune response), and EBV Research (investigating viral links to MS). Supporting infrastructure includes a Regenerative Medicine Laboratory for cell production and a CSF Bank for biomarker research. The organization also operates multiple fundraising channels including online donations, employer matching, planned giving, and athletic fundraising programs.

Differentiator

Problem solved

Functional benefit

Products and services

Stem Cell Clinical Trial (MSC-NP Therapy) FDA-approved Phase I and II clinical trials investigating the use of mesenchymal stem cell-derived neural progenitors (MSC-NPs) harvested from a patient's own bone marrow, transformed into neural progenitors in the lab, and injected intrathecally into spinal fluid to promote myelin repair and regeneration. Indicated for progressive MS patients with limited treatment options.
Organoid Modeling Service Production of cerebral organoids (mini-brains) and spinal cord organoids from patient-derived pluripotent stem cells. These 3D models allow study of disease progression in controlled experimental systems that mimic brain structure, examining cell proliferative capacity, neuronal differentiation, white matter analysis, and environmental factors influencing MS.
PPMS Animal Model World's first animal model specifically developed for primary progressive MS, created via intrathecal injection of PPMS patient cerebrospinal fluid into mouse cervical spinal cord. The model exhibits hallmark MS pathology including demyelination, reactive astrogliosis, and axonal damage.
Cerebrospinal Fluid (CSF) Bank Repository of patient cerebrospinal fluid specimens used for biomarker research and investigation of disease mechanisms. CSF specimens enable study of neural repair, disease activity markers, and treatment response in MS patients.
B-cell Library and Antibody Response Research Long-term research initiative to fully characterize the B-cell antibody response in MS. A library of patient-derived B-cells is continuously tested to search for immunodominant myelin proteins and isolate the trigger agent of the disease.
Epstein-Barr Virus (EBV) Research Program Investigation of EBV's role in MS pathogenesis using brain organoid models exposed to EBV. Studies mechanisms by which EBV contributes to MS and investigates EBV-related immune activation markers in response to different treatments and disease stages.
Regenerative Medicine Laboratory (Clinical-Grade MSC-NP Manufacturing) State-of-the-art cell production facility for manufacturing clinical-grade doses of autologous MSC-NPs for cell therapy treatments in clinical trial subjects with MS.
Donation and Fundraising Program Multiple donation options including online giving, employer matching, planned giving (wills/estates, IRA QCDs, trusts), gifts of stock, Team Tisch MS athletic fundraising, and custom fundraising event support.

Quantifiable outcome

Phase II trial: 76% of participants saw improved bladder function
+3 more outcomes

Companies that use Tisch MS Research Center of New York

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Tisch MS Research Center of New York technology and API

Technology

Technology focussed Yes

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

Feature5 records

Tisch MS Research Center of New York partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

Montreal Neurological Institute at McGill UniversitycoreStrategic or Co-development Partner · 20 January 2026Dr. Jo Anne Stratton, Assistant Professor of Neuroimmunology, visited for research seminar on ependymal cells at the brain-CSF interface. Her research on ependymal cell dysregulation in MS complements Tisch MSRCNY's CSF autoantibody research led by Dr. Jamie Wong. Collaboration planned to identify disease-relevant CSF-associated autoantibodies and investigate their effects on ependymal cells.
The Wistar InstitutecoreStrategic or Co-development Partner · 10 December 2025Dr. Paul M. Lieberman, Hilary Koprowski Endowed Professor and Program Leader at Wistar Institute's Genome Regulation and Cell Signaling Program, visited for Grand Rounds session. Wistar focuses on Epstein-Barr virus (EBV) and Kaposi's Sarcoma-associated Herpesvirus (KSHV) research exploring how viruses establish latent infections leading to cancer or autoimmune disorders. Tisch MSRCNY's EBV specialist Dr. Roberto Alfonso discussed lab findings and virology initiatives with Dr. Lieberman, with plans to deepen institutional relationship.
International Multiple Sclerosis Management Practice (IMSMP)coreStrategic or Co-development PartnerIMSMP is the clinical practice affiliated with Tisch MSRCNY. Together they constitute the largest independent MS center in the world. The co-located, integrated model allows seamless interaction between doctors and scientists, with over 80 staff members dedicated to MS. This unique partnership enables rapid translation of research to clinical practice.
PolycarbinminorOthersPartnership for pipette tip box and rack recycling. Tisch partners with Polycarbin to collect and recycle specialized lab plastic, substantially reducing the lab's plastic footprint.
Neurapheresis Research ConsortiumcoreStrategic or Co-development PartnerTisch MSRCNY is a member of the Neurapheresis Research Consortium, geared towards advancing the use of CSF filtration therapy in various neurological conditions including PPMS and sALS.

Scale indicators7 records

Recent moves9 records

Expansion highlights5 records

Tisch MS Research Center of New York competitors and assessment

Company assessment

Broad incumbents

National Multiple Sclerosis Society: Largest US MS nonprofit funding research, advocacy, and patient programs, including grants to centers like Tisch. They are the dominant funder/convener in the same disease space and set research-agenda priorities Tisch responds to.
Johns Hopkins Multiple Sclerosis Center: Leading academic MS center with strong neuroimmunology and remyelination research programs. A scaled incumbent with comparable translational depth competing for federal and foundation funding.
Brigham Multiple Sclerosis Center (Mass General Brigham): Harvard-affiliated MS center with strong clinical trial portfolio and biomarker/translational research. Competes directly with Tisch for top-tier MS clinical trials and translational faculty.
Mayo Clinic Multiple Sclerosis Center: Major academic MS center with deep clinical and translational programs, large tissue banks, and substantial NIH funding. A scaled academic incumbent competing for talent, trials, and grants in the same disease.

Direct peers

Rocky Mountain Multiple Sclerosis Center: Independent nonprofit MS center in Colorado delivering integrated clinical care and research, including stem cell and rehabilitation research. Closest direct peer to Tisch by structure (independent, integrated research+care, MS-only focus).
Mellen Center for Multiple Sclerosis Treatment and Research (Cleveland Clinic): Cleveland Clinic's flagship integrated MS program combining clinical care, imaging research, and clinical trials across the MS spectrum. Directly comparable to Tisch's IMSMP/MSRCNY integration model and a competitor for clinical-trial referrals and grant dollars in progressive MS.
Yale Multiple Sclerosis Center: Yale-based academic MS center running clinical trials and translational neuroimmunology research. Comparable academic translational MS program competing for grant funding and trial enrollment.
Accelerated Cure Project for Multiple Sclerosis: Patient-founded MS research nonprofit focused on curing MS through data, biospecimen repositories, and research networks. Closely comparable nonprofit mission and translational-research orientation to Tisch.

Others

International Progressive MS Alliance: Global funding collaborative dedicated to advancing research in progressive MS. A research funder and convener whose grant decisions shape Tisch's funding landscape and research direction.

Regional players

Multiple Sclerosis Association of America: US-focused MS nonprofit providing patient support, advocacy, and educational programs distinct from the National MS Society. Comparable patient-centric nonprofit in the same disease area but with less research-funding overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Tisch MS Research Center of New York financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tisch MS Research Center of New York leadership team

Management profile

Number of profiles

Profiles9 records

Tisch MS Research Center of New York funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tisch MS Research Center of New York M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tisch MS Research Center of New York

What does Tisch MS Research Center of New York do?

Is Tisch MS Research Center of New York a public or private company?

Tisch MS Research Center of New York is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Tisch MS Research Center of New York founded?

Tisch MS Research Center of New York was founded in 2006. It employs 101 to 250 people.

Where is Tisch MS Research Center of New York based?

Tisch MS Research Center of New York is headquartered in New York, United States, in the North America region.

How does Tisch MS Research Center of New York make money?

Three revenue lines are on record. Private Philanthropy and Donations are the primary driver. The others are foundation and Government Grants and clinical Care Revenue.

Who are Tisch MS Research Center of New York's main competitors?

Broad incumbents on record are National Multiple Sclerosis Society, Johns Hopkins Multiple Sclerosis Center, Brigham Multiple Sclerosis Center (Mass General Brigham) and Mayo Clinic Multiple Sclerosis Center. Direct peers are Rocky Mountain Multiple Sclerosis Center, Mellen Center for Multiple Sclerosis Treatment and Research (Cleveland Clinic), Yale Multiple Sclerosis Center and Accelerated Cure Project for Multiple Sclerosis. International Progressive MS Alliance is listed as an others. Multiple Sclerosis Association of America is listed as a regional player.

Does Tisch MS Research Center of New York have an API?

No public API is recorded for Tisch MS Research Center of New York.

What industry is Tisch MS Research Center of New York in?

Tisch MS Research Center of New York's product category is Medical Research Services. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS). Its NAICS code is 541714 and its SIC code is 8000.